Argenx Se (ARGX) Non-Current Deffered Revenue (2016 - 2020)

Argenx Se (ARGX) posted quarterly Non-Current Deffered Revenue of $249.5 million for Q4 2020, up 0.56% year-on-year from $248.1 million in Q1 2020, and up 8.24% on a QoQ basis from $230.5 million in Q2 2020.

Argenx Se (ARGX) Non-Current Deffered Revenue (2016 - 2020) Analysis & Trends

Argenx Se (ARGX) has reported Non-Current Deffered Revenue for 4 consecutive years, with $249.5 million the latest figure, recorded in Q4 2020.

  • Quarterly Non-Current Deffered Revenue rose 0.56% year-over-year to $249.5 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $249.5 million (up 0.56% YoY) and the FY2020 annual result came in at $269.0 million, up 9.84% from the prior year.
  • Non-Current Deffered Revenue rose to $249.5 million in Q4 2020 per ARGX's latest filing, from $230.5 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for ARGX reached as high as $270.5 million in Q2 2019 and fell as low as $2.1 million in Q4 2017.
  • A 4-year average of $169.2 million and a median of $239.3 million in 2020 frame the typical range for Non-Current Deffered Revenue.
  • Annual changes were most pronounced in 2017 — Non-Current Deffered Revenue tumbled 85.75% — and 2020, when it rose 0.56%.
  • Year by year, Non-Current Deffered Revenue stood at $14.5 million in 2016, then slumped by 85.75% to $2.1 million in 2017, then soared by 11880.19% to $248.1 million in 2019, then rose by 0.56% to $249.5 million in 2020.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $249.5 million, $230.5 million, and $248.1 million for Q4 2020, Q2 2020, and Q4 2019 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 225.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Alnylam Pharmaceuticals 35.71 Bn 32.70 Bn 959.66 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2020 249.49 Mn
Jun 30, 2020 230.50 Mn
Dec 31, 2019 248.11 Mn
Jun 30, 2019 270.45 Mn
Dec 31, 2017 2.07 Mn
Dec 31, 2016 14.53 Mn